Title:
PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING ANTICANCER VIRUS, IMMUNE CHECKPOINT INHIBITOR AND HYDROXYUREA AS ACTIVE INGREDIENTS
Document Type and Number:
WIPO Patent Application WO/2021/040065
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for treating cancer comprising an anticancer virus, an immune checkpoint inhibitor and hydroxyurea as active ingredients. The pharmaceutical composition for treating cancer of the present invention, comprising an anticancer virus, an immune checkpoint inhibitor and hydroxyurea as active ingredients, has an excellent anticancer effect and safety as compared to a conventional case of single administration of an anticancer virus or combined administration of an anticancer virus and an immune checkpoint inhibitor. Accordingly, the pharmaceutical composition for treating cancer of the present invention, comprising an anticancer virus, an immune checkpoint inhibitor and hydroxyurea as active ingredients, can be effectively used in treating cancer.
Inventors:
HWANG TAE-HO (KR)
CHO MONG (KR)
CHO MONG (KR)
Application Number:
PCT/KR2019/010850
Publication Date:
March 04, 2021
Filing Date:
August 26, 2019
Export Citation:
Assignee:
BIONOXX INC (KR)
International Classes:
A61K35/76; A61K31/155; A61K39/00; A61K39/395; A61P35/00
Domestic Patent References:
| WO2010135242A1 | 2010-11-25 | |||
| WO2018195552A1 | 2018-10-25 |
Foreign References:
| KR20190059421A | 2019-05-31 | |||
| KR20170033364A | 2017-03-24 | |||
| KR20180099557A | 2018-09-05 |
Other References:
LIU, Z. ET AL: "Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy", NATURE COMMUNICATIONS, vol. 8, 27 March 2017 (2017-03-27), pages 14754, XP055452350
See also references of EP 4023232A4
See also references of EP 4023232A4
Attorney, Agent or Firm:
FIRSTLAW P.C. (KR)
Download PDF: